INTECH Investment Management’s Axsome Therapeutics AXSM Stock Holding History

INTECH Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.68M	Sell	9,919 -4,509	-31%	-$779K	0.02%	778
2025 Q4	$2.64M	Sell	14,428 -1,621	-10%	-$226K	0.02%	615
2025 Q3	$1.95M	Sell	16,049 -6,907	-30%	-$778K	0.02%	792
2025 Q2	$2.4M	Buy	22,956 +2,658	+13%	+$281K	0.02%	654
2025 Q1	$2.37M	Buy	20,298 +4,270	+27%	+$486K	0.02%	668
2024 Q4	$1.36M	Buy	16,028 +5,087	+46%	+$468K	0.01%	945
2024 Q3	$983K	Buy	+10,941	New	+$955K	0.01%	813

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

INTECH Investment Management's AXSM Position: Q1 2026 in Review

INTECH Investment Management reduced its Axsome Therapeutics (AXSM) stake by 31% in Q1 2026, selling an estimated $779K and leaving 9,919 shares worth $1.68M. The position accounts for 0.02% of the portfolio, ranked #778.

INTECH Investment Management first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.64M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

INTECH Investment Management held 9,919 shares of Axsome Therapeutics worth $1.68M as of Q1 2026.
INTECH Investment Management sold 4,509 Axsome Therapeutics shares in Q1 2026, an estimated $779K.
Axsome Therapeutics made up 0.02% of INTECH Investment Management's portfolio in Q1 2026, its #778 holding.
INTECH Investment Management first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
INTECH Investment Management's Axsome Therapeutics position peaked at $2.64M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.